

GBT HOPE STUDY

Global Blood Therapeutics has launched the **GBT HOPE** (Hemoglobin **Q#111** polymErization) study, a global clinical research study to evaluate a new potential treatment for sickle cell disease, GBT440.

What is GBT440?

GBT440 is a potential therapy for patients with sickle cell disease that is designed to attack sickle hemoglobin, the cause of the disease. GBT440 works by helping hemoglobin, the molecules inside red blood cells, hold onto more oxygen as the red blood cells travel through the body. This may help keep red blood cells in their normal shape and stop sickling.

OXYGEN
O)4.5&


